Every 8-K that HCA Healthcare, Inc. (HCA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HCA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCA filings page.
HCA Inc., a direct wholly owned subsidiary of HCA Healthcare, Inc., increased the maximum size of its commercial paper program on July 29, 2026. The program’s aggregate face or principal amount outstanding at any time was raised from $4.0 billion to $8.0 billion.
The unsecured commercial paper notes issued under this program are unconditionally guaranteed by HCA Healthcare, Inc., and all other terms of the program remain unchanged. The notes and related guarantee are not registered under the Securities Act of 1933 and may be offered or sold in the United States only pursuant to an applicable exemption.
HCA Healthcare reported solid second quarter 2026 results with revenues of $20.230 billion, up 8.7% from a year earlier. Net income attributable to HCA was $1.699 billion and diluted EPS rose to $7.62 (adjusted EPS $7.59). Adjusted EBITDA increased to $4.027 billion, while same facility admissions grew 2.5%, equivalent admissions 2.7% and emergency room visits 3.6%. Same facility inpatient and outpatient surgeries declined 2.3% and 3.4%, respectively.
Results reflected a payer mix shift from higher uninsured volume tied to health insurance exchanges, which HCA estimates reduced income before income taxes by about $400 million in the quarter. This was partly offset by approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, largely from a Florida directed payment program that added $1.372 billion of revenues and $829 million of other operating expenses for periods back to October 1, 2024.
For the first six months of 2026, revenues were $39.339 billion and net income attributable to HCA was $3.319 billion (EPS $14.77). As of June 30, 2026 HCA held $1.013 billion in cash, $49.718 billion of total debt and $63.250 billion of total assets. Operating cash flow for the quarter was $2.335 billion. Capital expenditures in the quarter were $1.231 billion, and HCA repurchased 4.752 million shares for $2.064 billion, leaving $7.210 billion under its authorization. The board declared a quarterly cash dividend of $0.78 per share, payable September 30, 2026.
HCA updated its 2026 outlook, now guiding to revenues of $77.000 to $79.500 billion, net income attributable to HCA of $6.300 to $6.700 billion, Adjusted EBITDA of $15.400 to $16.100 billion, and diluted EPS of $28.70 to $30.50. The company raised its estimated unfavorable impact from health insurance exchanges on 2026 income before income taxes to $(1.000) to $(1.200) billion, from $(600) to $(900) million, and increased its expected Medicaid Supplemental Payment Programs net benefit to $300 to $500 million, from a prior estimate of $(50) to $(250) million. The 2026 capital expenditure estimate of $5.0 to $5.5 billion, excluding acquisitions, remains unchanged.
HCA Healthcare released preliminary second-quarter 2026 results and reduced its 2026 outlook. Q2 revenues are expected at $20.230 billion, up from $18.605 billion a year earlier. Net income attributable to HCA is estimated at $1.699 billion, or $7.62 per diluted share, versus $1.653 billion, or $6.83 per share. Adjusted EBITDA is projected at $4.027 billion, compared with $3.849 billion.
Operationally, same-facility admissions and equivalent admissions grew 2.5% and 2.7%, and emergency room visits rose 3.6%, while inpatient and outpatient surgeries declined 2.3% and 3.4%. Management estimates a payer mix shift toward more uninsured patients reduced income before income taxes by about $400 million, partially offset by roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, mainly in Florida.
For 2026, HCA now guides to revenues of $77.0–$79.5 billion, net income of $6.3–$6.7 billion, Adjusted EBITDA of $15.4–$16.1 billion, and diluted EPS of $28.70–$30.50, all lower than prior ranges, while keeping capital expenditures at $5.0–$5.5 billion.
HCA Healthcare, Inc. announced that Dr. Michael Cuffe, its Executive Vice President and Chief Clinical Officer, will step down from his role effective August 31, 2026.
He will remain with the company in a transitional role until February 2027 and will be eligible for benefits under HCA Healthcare’s executive severance policy and applicable incentive plans.
HCA Healthcare, Inc. reported that its subsidiary HCA Inc. has completed a public debt offering of $3.0 billion in senior unsecured notes, all guaranteed by HCA Healthcare on a senior unsecured basis. The offering consists of $1.0 billion of 4.700% Senior Notes due May 15, 2031, $750 million of 5.000% Senior Notes due May 15, 2033, and $1.25 billion of 5.300% Senior Notes due May 15, 2036, issued under an existing base indenture and new supplemental indentures.
Interest on each series is payable semi-annually on May 15 and November 15, beginning November 15, 2026, to holders of record as of May 1 or November 1. The notes rank as senior unsecured obligations of HCA Inc., are fully and unconditionally guaranteed by HCA Healthcare, and are subject to covenants that limit certain liens, sale-leaseback transactions, and major corporate restructurings. HCA Inc. may redeem some or all of the notes at specified redemption prices, and on a qualifying change of control combined with ratings downgrade, holders can require HCA Inc. to repurchase their notes at 101% of principal plus accrued interest.
HCA Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on April 23, 2026. A total of 209,777,472 shares of common stock were represented in person or by proxy out of 223,568,966 shares outstanding and entitled to vote as of the record date.
Stockholders elected nine directors to one-year terms, with each nominee receiving more votes "For" than "Against." They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved a non-binding advisory resolution on named executive officer compensation, and two stockholder proposals—one requesting a report on healthcare consequences and another on shareholders’ right to act by written consent—did not receive sufficient support for approval.
HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., plans a public offering of senior unsecured notes, with final terms such as maturity, interest rate and principal amount to be set at pricing. The notes will be issued under an effective shelf registration.
HCA Inc. has given notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026 on May 27, 2026, subject to receiving net proceeds from the new offering. HCA Inc. intends to use net proceeds for general corporate purposes, which may include repaying borrowings under its $4.000 billion commercial paper program and redeeming some or all of these 2026 notes.
HCA Healthcare, Inc. reported first quarter 2026 results showing modest growth and solid cash generation. Revenues rose 4.3% to $19.109 billion, while net income attributable to HCA increased 0.6% to $1.620 billion. Diluted earnings per share climbed 10.9% to $7.15, helped by share repurchases.
Adjusted EBITDA grew 1.9% to $3.802 billion, and cash flows from operating activities increased 22.0% to $2.014 billion. Management noted weaker seasonal respiratory volumes and weather-related impacts, largely offset by certain Medicaid supplemental program recognition.
The company continued significant capital deployment, with $1.119 billion in capital expenditures and repurchase of 3.157 million shares for $1.571 billion. The board declared a quarterly dividend of $0.78 per share, payable June 30, 2026. HCA reaffirmed its full-year 2026 guidance, including projected revenues of $76.5–$80.0 billion and Adjusted EBITDA of $15.55–$16.45 billion.
HCA Healthcare, Inc. adopted a 2026 Executive Officer Performance Excellence Program that pays cash performance awards to executive officers based on financial and quality results. Awards are weighted 80% on EBITDA targets and 20% on quality metrics covering infections and sepsis, complications and mortality, and care experience.
For EBITDA, payouts range from 25% of the EBITDA portion at threshold performance to 200% at maximum performance, with 100% at target. For each quality metric, payouts range from 0% at or below threshold to 200% at maximum, but no quality payout is made if actual EBITDA is less than 90% of the EBITDA target. The Compensation Committee may adjust metrics and results for unusual events, and awards are subject to discretionary and mandatory clawbacks, including in the case of restated results or specified misconduct. HCA also disclosed that director Robert J. Dennis will not stand for re-election and will retire from the Board at the April 23, 2026 annual meeting.
HCA Healthcare, Inc. reported that it issued a press release with its results of operations for the fourth quarter and full year ended December 31, 2025, made available as Exhibit 99.1.
The company also announced that its Board of Directors authorized an additional share repurchase program for up to $10 billion of its outstanding common stock, with repurchases to be made from time to time in the open market, through privately negotiated transactions, or otherwise, in accordance with applicable securities laws.
In addition, the Board declared a quarterly cash dividend of $0.78 per share on HCA common stock, payable on March 31, 2026 to stockholders of record at the close of business on March 17, 2026. These capital return actions highlight ongoing distributions to shareholders through both repurchases and cash dividends.
HCA Healthcare, Inc. announced that its subsidiary HCA Inc. completed a public offering of $3,250,000,000 aggregate principal of senior unsecured notes, guaranteed by HCA Healthcare. The tranches include $500,000,000 of 4.300% notes due 2030, $1,000,000,000 of 4.600% notes due 2032, $1,000,000,000 of 4.900% notes due 2035, and $750,000,000 of 5.700% notes due 2055.
Interest is payable semi‑annually on May 15 and November 15, starting May 15, 2026. The notes are senior unsecured obligations of HCA Inc., rank equally with its other senior debt, are effectively junior to secured debt to the extent of collateral value, and are structurally junior to liabilities of subsidiaries. They carry a full and unconditional senior unsecured guarantee from HCA Healthcare.
The notes may be redeemed at the issuer’s option at the redemption prices set in the indentures. If certain changes of control occur together with a qualifying ratings downgrade, holders can require repurchase at 101% of principal plus accrued interest. The securities were issued off an effective Form S‑3 shelf and governed by the existing base indenture and supplemental indentures.
HCA Healthcare, Inc. announced a proposed public offering of senior unsecured notes by its wholly owned subsidiary, HCA Inc., and issued a notice to redeem all $1.500 billion of its 5.875% senior notes due 2026 on November 26, 2025. The redemption is conditioned upon the Issuer’s receipt of net proceeds from the new offering prior to the redemption date.
The company stated that forward‑looking statements include the expected use of proceeds from the offering. This update outlines a refinancing step that replaces upcoming 2026 debt with new senior notes, pending successful completion of the offering.
HCA Healthcare, Inc. reported that it issued a press release covering its results for the third quarter ended September 30, 2025, and declared a quarterly cash dividend.
The Board approved a $0.72 per-share dividend on common stock, payable on December 29, 2025 to shareholders of record at the close of business on December 15, 2025. The Q3 results press release is included as Exhibit 99.1.